摘要
Abstract
Objective:To investigate the clinical efficacy of combined application of edaravone and dexborneol with tirofiban in the treatment of patients with acute cerebral infarction.Method:A total of 82 patients with acute cerebral infarction admitted to Quanzhou First Hospital Affiliated to Fujian Medical University between September 2023 and October 2024 were selected and randomly divided into two groups,with 41 cases in each group.Both groups received standard symptomatic treatment,supplemented by tirofiban therapy in the control group and tirofiban combined with edaravone injection in the study group.The therapeutic efficacy,National Institutes of Health Stroke Scale(NIHSS)score,high sensitivity C-reactive protein(hs-CRP),Barteh index(BI),tumor necrosis factor-α(TNF-α),neutrophil to lymphocyte ration(NLR),and safety were compared between the two groups.After 14 days of treatment,the two groups were followed up for 3 months,and the modified Rankin Scale(mRS)scores were compared.Result:After 14 days of treatment,the study group demonstrated a higher total effective rate compared to that in the control group,the BI score in the study group was higher than that in the control group,while the NIHSS score,hs-CRP,NLR,and TNF-α levels were lower than those in the control group,with statistically significant differences(P<0.05).At the 3-month follow-up,the study group exhibited superior mRS scores compared to the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion:For patients with acute cerebral infarction,the combined therapy of edaravone and dexborneol with tirofiban demonstrates reliable efficacy and a favorable safety profile.This treatment regimen effectively inhibits the inflammatory response,promotes the recovery of neurological deficits,aids in restoring patients'ability to live independently,and contributes to achieving a favorable prognosis.关键词
急性脑梗死/依达拉奉右莰醇/日常生活能力/神经功能/炎症/安全性Key words
Acute cerebral infarction/Edaravone dexborneol/Activity of daily living/Neurological function/Inflammation/Safety
